Please login to the form below

liraglutide

This page shows the latest liraglutide news and features for those working in and with pharma, biotech and healthcare.

Xultophy is a combination of insulin degludec and Novo’s glucagon-like peptide-1 (GLP-1) receptor agonist, liraglutide, which it markets as Victoza.

Novo Nordisk launches late-stage study in Alzheimer’s disease

of 3.6 years, a total number of 47 people were identified with development of dementia, of which 32 were on placebo and 15 on GLP-1 (liraglutide or semaglutide).
Novo Nordisk set to acquire Emisphere Technology for $1.8bn

Rothwell, chairman of Emisphere. Novo’s GLP-1 agonist franchise also includes Ozempic (semglutide) and Victoza (liraglutide).
Novo bolstered by new diabetes, obesity products

The once-weekly injectable GLP-1 agonist has continued to offset declines of Novo’s older drugs, including the one-daily shot Victoza (liraglutide).
Novo Nordisk taps Noom for digital help with its push into obesity

Novo Nordisk is already making headway in the obesity therapy market with injectable GLP-1 agonist Saxenda (liraglutide), which made $390m in sales in the first half of the year, up
Novo Nordisk gets FDA okay for new diabetes hope

injectable Ozempic – also based on semaglutide – and once-daily shot Victoza (liraglutide).

More from news
Approximately 14 fully matching, plus 113 partially matching documents found.

Novo Nordisk’s Klaus Henning Jensen on trends in medical affairs

Novo Nordisk's Victoza (liraglutide) is a GLP-1 receptor agonist. It was around this time that Novo began gearing up for launch of its future blockbuster diabetes treatment Victoza (liraglutide),

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Early Access Program - Regulatory Affairs (EAP-RA): Highly competitive salary

Associate Director - Global Healthcare Consulting: Highly competitive salary

Add my company

Medscape Medical Affairs enables all medical affairs professionals to take a more strategic leadership role, and maximize the impact of...

Virtual Patient Engagement Program: A Customer Story: Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
Humancomms for humancare?: Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
Rare diseases: not so rare after all: The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...

Email:
Password: